The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Invokana Diabetic Acidosis and Amputation Risks. There are currently at least 445 product liability and personal injury lawsuits filed against Johnson & Johnson the world’s largest pharmaceutical company and its subsidiary Janssen Pharmaceuticals in the federal court system.

Invokana Diabetic Acidosis and Amputation Risks
Invokana Diabetic Acidosis and Amputation Risks. According to many lawsuits, Invokana is linked to kidney failure, heart attacks, leg amputations and a build up of acid in the body known as diabetic ketoacidosis

These Invokana lawsuits claim that inadequate warnings were provided for diabetic patients and doctors about the potentially serious and catastrophic side effects of Invokana.

Invokana Amputation Injuries

Invokana is linked to kidney failure, urinary tract infections, leg amputations and diabetic ketoacidosis according to lawsuits and medical research.

What is Invokana?

Invokana (canagliflozin) is a new type 2 diabetic medication released in March 2013 and has been touted by Janssen Pharmaceuticals and Johnson & Johnson as being superior to the older types of diabetic medications.

Invokana increases the amount of sugar excreted in the urine. Invokana has been plagued by the FDA over its severe side effects and injuries and the FDA has required several Invokana warning updates.

FDA Invokana Warnings

In December 2015, the FDA required Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, highlighting that the medication significantly increases the risk of this potentially deadly condition.

Patients were advised by the FDA to stop taking Invokana and seek medical attention immediately if they have any symptoms of ketoacidosis, a serious condition in which the body produces high levels of blood acids called ketones. The FDA warning included data about severe urinary tract infections from Invokana use.

In June 2016, the FDA required additional label warnings about the link between Invokana and kidney risks, highlighting that the medication may increase the risk of acute kidney injury.

Invokana doubles Amputation risk according to studies

Based on new data from two large clinical trials, the FDA in May 2017 concluded that the type 2 diabetes medicines Invokana, Invokamet, Invokamet XR caused an increased risk of leg and foot amputations.

The FDA is requiring new warnings, including their most prominent Boxed Warning, to be added to the Invokana drug labels to describe this risk.

Final results from two clinical trials – the CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus) – showed that leg and foot amputations occurred about twice as often in patients treated with Invokana compared to patients treated with placebo, which is an inactive treatment.

Invokana Federal Multidistrict Litigation

Since December 2016, all federally-filed Invokana injury lawsuits have been consolidated as part of the Invokana multidistrict litigation (MDL), which is centralized before U.S. District Judge Brian Martinotti in the District of New Jersey to coordinate discovery and pretrial proceedings.

If you or someone you know succumbed to an Invokana Ketoacidosis, leg amputations or kidney failure from taking Invokana for the treatment of their type 2 diabetes, please call us for further information at 888-210-9693. Dr. Shezad Malik Law Firm is investigating Invokana Ketoacidosis, leg amputations or kidney failure from taking Invokana for the treatment of their type 2 diabetes.

Comments are closed.

Of Interest